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 Plant Biologist Shruti Lal,  
PhD, Identifies New Molecule 
That Could Prove Key in 
Treating Pancreatic Cancer
When Shruti Lal, PhD, joined the 
Division of Surgical Research as a  
post-doctoral researcher, she brought 
an intriguing blend of experience to  
the lab.
A veritable Renaissance woman, 
Dr. Lal has earned Master’s degrees 
in both Botany and Computational 
Biosciences. She holds a two-year 
diploma in e-commerce and web 
design, and has more than six years 
of professional experience in software 
development, teaching and research. 
She also studied Molecular Biology 
techniques at the U.S. Department of 
Energy’s Joint Genome Institute and 
explored microarray printing, scanning 
and hybridization at the University of 
California, San Francisco.
As a doctoral student at the University 
of California, Riverside, Dr. Lal studied 
the molecular mechanism that controls 
floral specification in the model plant 
Arabidopsis thaliana. Her goal was to 
establish the gene regulatory networks 
(GRNs) that promote flowering and 
floral specification in Arabidopsis.  
She applied a variety of approaches – 
including molecular, genomic and 
bioinformatics – to understand these 
networks.
As Dr. Lal explains, plants and animals 
have a fundamental difference. 
While human children are essentially 
miniature versions of human adults, a 
young plant is not simply a mini-model 
of an adult plant: “The plant at juvenile 
stage has leaves and stems, but upon 
transition to adult stage it initiates new 
organs such as flowers,” Dr. Lal says. 
“My doctoral research was focused on 
understanding what changes occur that 
drive plants to start producing flowers.”
Despite opportunities to work in the 
field of plant research, Dr. Lal was eager 
to apply her skills to studying human 
disease. That desire led her to Jonathan 
Brody, PhD, Director of the Division 
of Surgical Research, who offered 
Dr. Lal a position focusing on cancer 
research. While it might not seem like 
the most logical career move, Dr. Brody 
explains, “Dr. Lal brings an intense 
dedication and fresh perspective to my 
research team that is invaluable.” From 
the outset, he posed two challenging 
questions to her: How do pancreatic 
cancer cells live with genetic mutations, 
and how do they become resistant to 
chemotherapies?
Identifying a novel  
HuR-regulated molecule
Jefferson scientists previously identified 
the RNA binding protein HuR 
(Human antigen R) as a key molecule 
in pancreatic cancer cells. More than 
half of patients with pancreatic cancer 
express high cytoplasmic levels of HuR 
and those patients are more likely to 
respond well to the drug gemcitabine 
than those with relatively low levels 
of HuR. While this knowledge is 
important, understanding exactly how 
HuR functions in pancreatic cancer 
cells is critical. This has been the focus 
of Dr. Lal’s research since joining the 
Jefferson team in November 2011. 
In that time, Dr. Lal has identified the 
mechanism by which HuR regulates 
the WEE1 molecule (a gate keeper 
of cell growth) when cancer cells are 
exposed to certain chemotherapeutic 
drugs. “When chemotherapy is used, 
pancreatic cancer cells with the HuR 
protein incur some damage but protect 
themselves by putting themselves on 
‘hold,’ and thereby prevent cell death,” 
Dr. Lal explains. 
Through the research, Dr. Lal has 
found that removing the HuR protein 
impairs WEE1 function and promotes 
cell death. Thus, Dr. Lal explains, if a 
chemotherapy drug can be designed to 
inhibit the interaction between HuR 
and WEE1, pancreatic cancer cells will 
be much more likely to die. 
With her groundbreaking manuscript 
currently in review, Dr. Lal’s long-term 
goal remains clear: “We want to quickly 
get this information from the bench 
to the bedside,” she says, noting that 
pancreatic cancer deaths are rising at 
an alarming rate, while other types of 
cancer deaths are steadily declining. 
“Our objective is to reverse that trend.” 
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Changing Lives Through Research
Randi Altmark, RN, BSN, CNOR
Through the American College of Surgeons 
National Surgical Quality Improvement 
Program (ACS NSQIP®), the Department  
of Surgery continually searches for ways  
to further improve the quality of 
surgical care delivered to our patients. 
As our NSQIP Surgical Clinical Nurse 
Reviewer, Randi Altmark plays a pivotal 
role in collecting and maintaining the 
data necessary to identify and act on 
opportunities for improvement.
When she returned to Jefferson to assume 
this role in 2006, Altmark brought more 
than 20 years of experience in nursing – 
including seven years as a Jefferson OR 
nurse and experience as an OR manager 
and business manager for surgical 
services as well as labor and delivery. 
Altmark maintains Jefferson’s ACS NSQIP 
database by abstracting relevant clinical 
data from patient charts. With data points 
spanning pre-op, intra-op and post-op 
variables, the database enables Jefferson 
to generate risk-adjusted reports and 
trend the quality of surgical care. As a 
participant in this program, Jefferson can 
benchmark itself against other hospitals 
in order to evaluate its own performance 
and cultivate best practices. In addition to 
maintaining the database, Altmark works 
closely with Surgeon Champions Herbert 
E. Cohn, MD, Scott Cowan, MD, and 
Stacey Milan, MD and other health care 
providers to develop and execute process 
improvements. 
The NSQIP program enables surgeons, 
anesthesiologists, nurses and other 
clinicians to view summaries of patient 
outcomes based on objective clinical data. 
Working with others, they can modify 
their practice to provide improved care to 
surgical patients. For example, NSQIP data 
has been used to help drive improvements 
in rates of surgical site infections.
 “It’s rewarding to know that my relatively 
small but vital contribution can greatly 
benefit patients receiving surgical care,” 
Altmark says. “And, I enjoy collaborating 
with surgeons and clinicians, who all 
contribute their expertise and unify 
around a common goal of providing the 
best-quality care possible for Jefferson 
patients.”
“Above all, I’m very grateful to work in  
a collaborative environment with people 
who recognize that while we’re doing a 
great job, we can always do better,”  
she concludes.
On the Job
“ ...if a chemotherapy drug 
can be designed to inhibit 
the interaction between 
HuR and WEE1, pancreatic 
cancer cells will be much 
more likely to die.”
Dr. Shruti Lal, PhD is conducting groundbreaking research on how the HuR protein  
regulates cell growth in pancreatic cancer cells.
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